Abstract
Abstract Soft tissue and visceral sarcomas (STS) constitute a heterogeneous group of rare connective tissue cancers, with very variable clinical presentations, and an estimated incidence of 5.6-5.9/100 000/year, over 100 different histotypes and even more molecular subtypes. Despite of this heterogeneity, sarcoma patients often receive similar treatment strategies in localized and advanced phase. This one-size-fits-all approach has largely failed to improve patient survival, either in localized phase or in advanced phase. Conversely, distinguishing patients on the basis of histology, or molecular alteration has been very efficient to identify active agents in individual sarcoma histotypes, in both localized and advanced phase. GIST, DFSP, IMT, PECOMAs, PVNS, GCTB, LGESS, NTRK sarcomas are examples of successes of personalized medicine of cancer, with a long term survival observed with a substantial proportion of patients. In this presentation, we will review the standard of care for medical treatments in localized and advanced phase and discuss the strategy to be implemented for a more efficient drug development in these rare tumors. We will describe successful and unsuccessful to develop precision medicine in sarcoma, in the field of targeted oncogene therapies and immunotherapy with anti-ICP.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call